Searchable abstracts of presentations at key conferences in endocrinology

ea0042il7 | Hormone and Disease | Androgens2016

Effects of long-term testosterone therapy on obesity, glycaemic control and other features of the metabolic syndrome

Saad Farid

Epidemiological studies show a high prevalence of hypogonadism in men with obesity, type 2 diabetes and other components of the metabolic syndrome. Restoring physiological concentrations of testosterone in hypogonadal men by long-term testosterone therapy of 5 years and longer has resulted in substantial weight loss and meaningful improvement of glycaemic control. Blood pressure was reduced and lipid pattern improved. The longer the observation time in real-life studies, the m...

ea0032p652 | Male reproduction | ECE2013

Fifteen years of experience with intramuscular testosterone undecanoate for substitution in male hypogonadism: beneficial effects on the metabolic syndrome and high safety profile

Zitzmann Michael , Saad Farid

Background: A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount for hypogonadal men. The i.m. injection of the long-acting ester testosterone undecanoate (TU) offers a convenient modality for testosterone substitution.Methods: We report data from 334 patients (147 with primary (including 38 Klinefelter patients), 100 with secondary hypogonadism and 87...

ea0020p290 | Clinical case reports and clinical reports | ECE2009

Intramuscular testosterone undecanoate – the experience of 11 years

Zitzmann Michael , Saad Farid , Nieschlag Eberhard

A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount in hypogonadal men. A feasible modality is the intramuscular injection of the long-acting ester testosterone undecanoate (TU).We report data from 183 patients (99 with primary, 70 with secondary hypogonadism and 14 with late-onset hypogonadism) aged 15–70 years (mean 37±12 years) receiving ...

ea0073oc2.3 | Oral Communications 2: Diabetes, Obesity, Metabolism and Nutritionw | ECE2021

Long-term testosterone therapy improves glycaemic control and weight control in men with type 2 diabetes: 12-year observational data from a controlled registry study in a urological setting

Saad Farid , Haider Karim Sultan , Haider Ahmad

BackgroundPrevalence of hypogonadism has been reported as high as 50% in men with T2DM and/or obesity. ADA and AACE Guidelines recommend assessment of hypogonadism in men with T2DM and obesity.Material and methodsIn a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg/12 weeks (T-group), 178 opted against treatment (CTRL). Changes over time between groups were compared an...

ea0073aep162 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Effects of long-term testosterone therapy on anthropometric parameters in men with functional hypogonadism and obesity: 12-year observational data from a controlled registry study in a urological setting

Saad Farid , Haider Karim Sultan , Haider Ahmad

BackgroundWhile almost all studies consistently show reduction of waist circumference as a result of testosterone therapy (TTh), effects on body weight are inconsistent and may depend on treatment duration, route of administration, and adherence.Material and methodsAfter excluding men with primary hypogonadism, 476 men with functional, symptomatic hypogonadism were obese. 281 men received testosterone undecan...

ea0073aep232 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Long-term testosterone therapy improves lipid profile in men with functional hypogonadism and overweight or obesity: 12-year observational data from a controlled registry study in a urological setting

Saad Farid , Haider Karim Sultan , Haider Ahmad

BackgroundEffects of testosterone therapy (TTh) on lipid parameters are inconsistent and may depend on treatment duration, route of administration, and adherence. While in short-term studies, testosterone usually lowers HDL, long-term studies seem to increase HDL. Total cholesterol, LDL and triglycerides are either reduced by TTh, or effects are neutral.Material and methodsAfter excluding men with primary hyp...

ea0035p478 | Diabetes therapy | ECE2014

Hypogonadal men with cardiovascular diseases benefit from long-term treatment with testosterone undecanoate: observational data from a registry study

Saad Farid , Haider Ahmad , Doros Gheorghe , Traish Abdulmaged

Background: Hypogonadism is associated with cardiometabolic risk. Studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone replacement therapy (TRT) in men with CVD.Methods: In a prospective, cumulative, observational registry study from a single urologist’s office, 300 men with testosterone...

ea0035p754 | Obesity | ECE2014

Meaningful and sustained weight loss and improvement of lipid profile in hypogonadal men on long-term treatment with testosterone undecanoate (TU) injections are independent of age: observational data from two registry studies

Saad Farid , Haider Ahmad , Yassin Aksam , Doros Gheorghe , Traish Abdulmaged

Introduction: Improvements of anthropometric and metabolic parameters on long-term testosterone replacement therapy (TRT) from our registry studies have been reported in 2013 (Saad, Obes; Yassin and Doros, Clin Obes; Traish, Int J Clin Pract).Methods: Five hundred and sixty-one hypogonadal men from both registry studies were divided into age groups ≤65 (Group A, n=450) and >65 years (Group B, n=111). All men were treated with ...

ea0035p755 | Obesity | ECE2014

Anthropometric and metabolic parameters in 46 hypogonadal men with obesity grade III improve upon long-term treatment with testosterone undecanoate (TU) injections: Observational data from two registry studies

Saad Farid , Haider Ahmad , Yassin Aksam , Doros Gheorghe , Traish Abdulmaged

Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m2) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining n...

ea0032p740 | Obesity | ECE2013

Obese hypogonadal men treated with testosterone undecanoate injections up to 5 years substantially and progressively lose weight

Saad Farid , Haider Ahmad , Doros Gheorghe , Traish Abdulmaged

Introduction: Abdominal adipose tissue suppresses testosterone production by various mechanisms affecting the hypothalamic–pituitary–gonadal axis. Hypogonadism leads to further accumulation of fat mass thus creating a vicious circle. This study analysed the effects of restoring testosterone in obese hypogonadal men.Methods: Cumulative, prospective, registry study of 181 men (mean age: 59.11±6.06 years) with testosterone levels below 12.1 n...